title: Do diabetes and obesity affect the metabolic response to exercise?
abstract: OBJECTIVE
  Exercise is recommended as therapeutic intervention for people at risk to develop type 2 diabetes to prevent or treat the disease. Recent studies on the influence of obesity and type 2 diabetes on the outcome of exercise programs are discussed.
  
  
  RESULTS
  Poor glycemic control before an intervention can be a risk factor of reduced therapeutic benefit from exercise. But the acute metabolic response to exercise and the transcriptional profile of the working muscle is similar in healthy controls and type 2 diabetic patients, including but not limited to intact activation of skeletal muscle AMP-activated kinase signaling, glucose uptake and expression of peroxisome proliferator-activated receptor gamma coactivator 1α. The increase in plasma acylcarnitines during exercise is not influenced by type 2 diabetes or obesity. The hepatic response to exercise is dependent on the glucagon/insulin ratio and the exercise-induced increase in hepatokines such as fibroblast growth factor 21 and follistatin is impaired in type 2 diabetes and obesity, but consequences for the benefit from exercise are unknown yet.
  
  
  CONCLUSIONS
  Severe metabolic dysregulation can reduce the benefit from exercise, but the intact response of key metabolic regulators in exercising skeletal muscle of diabetic patients demonstrates the effectiveness of exercise programs to treat the disease.
authors.affiliation: aThe Centre of Inflammation and Metabolism, Centre for Physical Activity Research bDepartment of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark cDivision of Endocrinology, Diabetology, Angiology, Nephrology, Pathobiochemistry and Clinical Chemistry, Department of Internal Medicine IV dInstitute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tuebingen eGerman Center for Diabetes Research (DZD), Tuebingen, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Plomgaard
authors.forename: Cora
authors.initials: C
authors.lastname: Weigert
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D001786:Blood Glucose / Q000032:analysis; D002331:Carnitine / Q000031:analogs & derivatives / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D015444:Exercise / Q000502:physiology*; D005227:Fatty Acids / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000378:metabolism; D018482:Muscle, Skeletal / Q000737:chemistry / Q000201:enzymology / Q000378:metabolism; D009765:Obesity / Q000378:metabolism* / Q000628:therapy*; D010084:Oxidation-Reduction; D000071248:Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha / Q000032:analysis; D015398:Signal Transduction
chemical_list: D001786:Blood Glucose; D005227:Fatty Acids; D000071248:Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; C116917:acylcarnitine; D006003:Glycogen; D055372:AMP-Activated Protein Kinases; D005947:Glucose; D002331:Carnitine